November 2024
·
80 Reads
This page lists works of an author who doesn't have a ResearchGate profile or hasn't added the works to their profile yet. It is automatically generated from public (personal) data to further our legitimate goal of comprehensive and accurate scientific recordkeeping. If you are this author and want this page removed, please let us know.
November 2024
·
80 Reads
November 2024
·
591 Reads
·
1 Citation
The Lancet
Background Over the past several decades, the overweight and obesity epidemic in the USA has resulted in a significant health and economic burden. Understanding current trends and future trajectories at both national and state levels is crucial for assessing the success of existing interventions and informing future health policy changes. We estimated the prevalence of overweight and obesity from 1990 to 2021 with forecasts to 2050 for children and adolescents (aged 5–24 years) and adults (aged ≥25 years) at the national level. Additionally, we derived state-specific estimates and projections for older adolescents (aged 15–24 years) and adults for all 50 states and Washington, DC. Methods In this analysis, self-reported and measured anthropometric data were extracted from 134 unique sources, which included all major national surveillance survey data. Adjustments were made to correct for self-reporting bias. For individuals older than 18 years, overweight was defined as having a BMI of 25 kg/m² to less than 30 kg/m² and obesity was defined as a BMI of 30 kg/m² or higher, and for individuals younger than 18 years definitions were based on International Obesity Task Force criteria. Historical trends of overweight and obesity prevalence from 1990 to 2021 were estimated using spatiotemporal Gaussian process regression models. A generalised ensemble modelling approach was then used to derive projected estimates up to 2050, assuming continuation of past trends and patterns. All estimates were calculated by age and sex at the national level, with estimates for older adolescents (aged 15–24 years) and adults aged (≥25 years) also calculated for 50 states and Washington, DC. 95% uncertainty intervals (UIs) were derived from the 2·5th and 97·5th percentiles of the posterior distributions of the respective estimates. Findings In 2021, an estimated 15·1 million (95% UI 13·5–16·8) children and young adolescents (aged 5–14 years), 21·4 million (20·2–22·6) older adolescents (aged 15–24 years), and 172 million (169–174) adults (aged ≥25 years) had overweight or obesity in the USA. Texas had the highest age-standardised prevalence of overweight or obesity for male adolescents (aged 15–24 years), at 52·4% (47·4–57·6), whereas Mississippi had the highest for female adolescents (aged 15–24 years), at 63·0% (57·0–68·5). Among adults, the prevalence of overweight or obesity was highest in North Dakota for males, estimated at 80·6% (78·5–82·6), and in Mississippi for females at 79·9% (77·8–81·8). The prevalence of obesity has outpaced the increase in overweight over time, especially among adolescents. Between 1990 and 2021, the percentage change in the age-standardised prevalence of obesity increased by 158·4% (123·9–197·4) among male adolescents and 185·9% (139·4–237·1) among female adolescents (15–24 years). For adults, the percentage change in prevalence of obesity was 123·6% (112·4–136·4) in males and 99·9% (88·8–111·1) in females. Forecast results suggest that if past trends and patterns continue, an additional 3·33 million children and young adolescents (aged 5–14 years), 3·41 million older adolescents (aged 15–24 years), and 41·4 million adults (aged ≥25 years) will have overweight or obesity by 2050. By 2050, the total number of children and adolescents with overweight and obesity will reach 43·1 million (37·2–47·4) and the total number of adults with overweight and obesity will reach 213 million (202–221). In 2050, in most states, a projected one in three adolescents (aged 15–24 years) and two in three adults (≥25 years) will have obesity. Although southern states, such as Oklahoma, Mississippi, Alabama, Arkansas, West Virginia, and Kentucky, are forecast to continue to have a high prevalence of obesity, the highest percentage changes from 2021 are projected in states such as Utah for adolescents and Colorado for adults. Interpretation Existing policies have failed to address overweight and obesity. Without major reform, the forecasted trends will be devastating at the individual and population level, and the associated disease burden and economic costs will continue to escalate. Stronger governance is needed to support and implement a multifaceted whole-system approach to disrupt the structural drivers of overweight and obesity at both national and local levels. Although clinical innovations should be leveraged to treat and manage existing obesity equitably, population-level prevention remains central to any intervention strategies, particularly for children and adolescents.
November 2024
·
28 Reads
Methods appendix to: GBD 2021 US Obesity Forecasting Collaborators. National-level and state-level prevalence of overweight and obesity among children, adolescents, and adults in the USA, 1990–2021, and forecasts up to 2050. Lancet 2024; published online Nov 14. https://doi.org/10.1016/S0140-6736(24)01548-4. This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors.
November 2024
·
25 Reads
Supplementary appendix 2. Results appendix to: GBD 2021 US Obesity Forecasting Collaborators. National-level and state-level prevalence of overweight and obesity among children, adolescents, and adults in the USA, 1990–2021, and forecasts up to 2050. Lancet 2024; published online Nov 14. https://doi.org/10.1016/S0140-6736(24)01548-4 This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors.
October 2024
·
56 Reads
October 2024
·
68 Reads
October 2024
·
77 Reads
October 2024
·
55 Reads
October 2024
·
776 Reads
Public Health
Objectives: In this study, the trends and current situation of the injury burden as well as attributable burden to injury risk factors at global, regional, and national levels based on the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019 are presented. Study design: To assess the attributable burden of injury risk factors, the data of interest on data sources were retrieved from the Global Health Data Exchange (GHDx) and analyzed. Methods: Cause-specific death from injuries was estimated using the Cause of Death Ensemble model in the GBD 2019. The burden attributable to each injury risk factor was incorporated in the population attributable fraction to estimate the total attributable deaths and disability-adjusted life years. The Socio-demographic Index (SDI) was used to evaluate countries' developmental status. Results: Globally, there were 713.9 million (95% uncertainty interval [UI]: 663.8 to 766.9) injuries incidence and 4.3 million (UI: 3.9 to 4.6) deaths caused by injuries in 2019. There was an inverse relationship between age-standardized disability-adjusted life year rate and SDI quintiles in 2019. Overall, low bone mineral density was the leading risk factor of injury deaths in 2019, with a contribution of 10.5% (UI: 9.0 to 11.6) of total injuries and age-standardized deaths, followed by occupational risks (7.0% [UI: 6.3-7.9]) and alcohol use (6.8% [UI: 5.2 to 8.5]). Conclusion: Various risks were responsible for the imposed burden of injuries. This study highlighted the small but persistent share of injuries in the global burden of diseases and injuries to provide beneficial data to produce proper policies to reach an effective global injury prevention plan.
October 2024
·
822 Reads
The Lancet Public Health
Background : Smoking is the leading behavioural risk factor for mortality globally, accounting for more than 175 million deaths and nearly 4·30 billion years of life lost (YLLs) from 1990 to 2021. The pace of decline in smoking prevalence has slowed in recent years for many countries, and although strategies have recently been proposed to achieve tobacco-free generations, none have been implemented to date. Assessing what could happen if current trends in smoking prevalence persist, and what could happen if additional smoking prevalence reductions occur, is important for communicating the effect of potential smoking policies. Methods : In this analysis, we use the Institute for Health Metrics and Evaluation's Future Health Scenarios platform to forecast the effects of three smoking prevalence scenarios on all-cause and cause-specific YLLs and life expectancy at birth until 2050. YLLs were computed for each scenario using the Global Burden of Disease Study 2021 reference life table and forecasts of cause-specific mortality under each scenario. The reference scenario forecasts what could occur if past smoking prevalence and other risk factor trends continue, the Tobacco Smoking Elimination as of 2023 (Elimination-2023) scenario quantifies the maximum potential future health benefits from assuming zero percent smoking prevalence from 2023 onwards, whereas the Tobacco Smoking Elimination by 2050 (Elimination-2050) scenario provides estimates for countries considering policies to steadily reduce smoking prevalence to 5%. Together, these scenarios underscore the magnitude of health benefits that could be reached by 2050 if countries take decisive action to eliminate smoking. The 95% uncertainty interval (UI) of estimates is based on the 2·5th and 97·5th percentile of draws that were carried through the multistage computational framework. Findings: Global age-standardised smoking prevalence was estimated to be 28·5% (95% UI 27·9–29·1) among males and 5·96% (5·76–6·21) among females in 2022. In the reference scenario, smoking prevalence declined by 25·9% (25·2–26·6) among males, and 30·0% (26·1–32·1) among females from 2022 to 2050. Under this scenario, we forecast a cumulative 29·3 billion (95% UI 26·8–32·4) overall YLLs among males and 22·2 billion (20·1–24·6) YLLs among females over this period. Life expectancy at birth under this scenario would increase from 73·6 years (95% UI 72·8–74·4) in 2022 to 78·3 years (75·9–80·3) in 2050. Under our Elimination-2023 scenario, we forecast 2·04 billion (95% UI 1·90–2·21) fewer cumulative YLLs by 2050 compared with the reference scenario, and life expectancy at birth would increase to 77·6 years (95% UI 75·1–79·6) among males and 81·0 years (78·5–83·1) among females. Under our Elimination-2050 scenario, we forecast 735 million (675–808) and 141 million (131–154) cumulative YLLs would be avoided among males and females, respectively. Life expectancy in 2050 would increase to 77·1 years (95% UI 74·6–79·0) among males and 80·8 years (78·3–82·9) among females. Interpretation: Existing tobacco policies must be maintained if smoking prevalence is to continue to decline as forecast by the reference scenario. In addition, substantial smoking-attributable burden can be avoided by accelerating the pace of smoking elimination. Implementation of new tobacco control policies are crucial in avoiding additional smoking-attributable burden in the coming decades and to ensure that the gains won over the past three decades are not lost. Funding: Bloomberg Philanthropies and the Bill & Melinda Gates Foundation.
... Ischemic stroke (IS) is one of the leading causes of global disability and mortality [1]. Despite advances in recent decades that have improved stroke care and reduced morbidity and mortality rates, these rates remain alarmingly high. ...
September 2024
The Lancet Neurology
... Most workers today face a complex mixture of exposures that may affect their health. This is illustrated Turner et al in Global Burden of Disease (GBD) studies, which continue to elaborate on various exposures and factors that affect disease risk such as stroke (29), while also elaborating on clusters of risks across the globe (30). Despite their evident value in gathering epidemiological evidence, we still lack sufficient knowledge about the mechanisms linking exposures or risk factors to outcomes such as health and wellbeing, as well as an understanding of potential mediating or moderating factors (31). ...
October 2024
The Lancet Neurology
... With an ageing global population and an increasing burden of non-communicable diseases such as musculoskeletal disorders, diabetes and stroke, healthcare systems are facing significant challenges [1]. In 2022, more than a fifth of the German population was aged 65 or older. ...
May 2024
The Lancet
... The present study utilized the latest data from the GBD 2021 database, a comprehensive global health repository encompassing detailed information on 371 diseases, 88 risk factors, and numerous injuries 11,12 . The primary data sources for GBD 2021 include vital registration systems, verbal autopsies, surveys, censuses, surveillance systems, and cancer registries, providing critical evidence for estimating disease incidence and mortality rates. ...
May 2024
The Lancet
... The methods used to forecast population, fertility, and all-cause mortality have been reported elsewhere. [32][33][34][35] Methods and accompanying estimates for smoking-specific inputs, including smoking prevalence, continuous measures of intensity of exposure, and dose-response relative risks for 32 health outcomes have also been previously published. 1 In this analysis, we only report the direct effects from smoking tobacco, which do not include the health effects from second-hand smoke, smokeless tobacco use, or electronic nicotine delivery systems. ...
March 2024
The Lancet
... Over the coming decades the population will see a significant increase in the number of people over the age of 65, who will require health services to meet their needs. Ireland, like many high-income countries are experiencing a reduction in fertility rates, which has the potential to affect birth rates and maternity services in the future (Bhattacharjee et al. 2024). With such a change in demographics there is a need to develop strategies that proactively respond to and manage the healthcare needs of the Irish population in the 21st century. ...
May 2024
The Lancet
... According to 2021 global statistics, the global mortality rate from CO poisoning is 0.366 per 100,000; with 28,900 deaths and 1,18 million cases across all ages. Nearly 70% of deaths occur in men, and the 50 -54 age group has the highest number of deaths [5]. ...
October 2023
The Lancet Public Health
... The above considerations are especially relevant for older populations, where CKD has per se a strong relationship with aging and age-related multimorbidity [5,14,15], which contribute to increased costs. CKD-related comorbidity and multimorbidity amplify the complexity of the disease, healthcare utilization, length of hospital stays, and impact prognosis [7,[16][17][18][19]. In this regard, recent studies have shown that direct costs of hospital admission of CKD patients with diabetes are considerably higher than those without diabetes [20,21]; similarly, the per patient per year and inpatient costs of CKD increased in patients with comorbid diabetes mellitus, cardiovascular disease, or heart failure [8,22]. ...
April 2023
... Details of the bias correction method are in appendix 1 (pp [30][31]. Briefly, using available US datasets with self-reported information and measured NHANES data, statistical models based on meta-regression-Bayesian, regularised, trimmed (MR-BRT) 51 were developed to estimate bias correction coefficients specific to each sex (male and female), 5-year age group (from age 5 years to age ≥80 years), and decade (1990-2000, 2000-10, 2010-21). The bias correction coefficients were applied to self-reported prevalence data from individuals aged 15 years and older. ...
October 2022
Nature Medicine
... LRIs remain the deadliest infectious disease globally, ranking as the fourth leading cause of death (1,2). They are particularly significant contributors to mortality in children under 5 years of age and adults over 70, resulting in more deaths than tuberculosis and HIV combined (3). Additionally, LRIs are associated with a range of potential complications and impose a substantial economic burden worldwide (4,5). ...
August 2022
The Lancet Infectious Diseases